Who is sponsoring NCT06222567?

NCT06222567 is sponsored by Onze Lieve Vrouwe Gasthuis.

What drugs are being tested in NCT06222567?

Interventions in NCT06222567: 15 minutes pumping with INITIATE program, 5 minutes extra pumping with MAINTAIN program.

What condition does NCT06222567 study?

NCT06222567 studies Breast Pumping.

Is NCT06222567 still recruiting?

NCT06222567 is currently completed. Last updated 24 January 2025.

Last reviewed 2025-01-24 · How we verify

NCT06222567

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Assessing the Effect of an Additional 5 Minutes Pumping on Milk Output in the First Days After Delivery

Completed NA Last updated 24 January 2025

What this trial tests

NA trial testing 15 minutes pumping with INITIATE program in Breast Pumping in 90 participants. Completed in 18 August 2023.

Timeline

6 February 2023

Primary endpoint
18 August 2023

18 August 2023

Quick facts

Lead sponsor	Onze Lieve Vrouwe Gasthuis
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	supportive care
Enrollment	90
Start date	6 February 2023
Primary completion	18 August 2023
Estimated completion	18 August 2023
Sites	1 location across Netherlands

Drugs / interventions tested

15 minutes pumping with INITIATE program
5 minutes extra pumping with MAINTAIN program

Conditions studied

Breast Pumping — all drugs for Breast Pumping →

Sponsor

Onze Lieve Vrouwe Gasthuis — full company profile →

Who can join

18 and older, female only, with Breast Pumping. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study hypothesizes that human who are both breastfeeding and pumping in the first days postpartum have more expression volume with an additional 5 minutes of pumping with Maintain program after pumping with the INITIATE program.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Onze Lieve Vrouwe Gasthuis trials

Trials by the same sponsor.

NCT05976256 — Kinesiotaping in Trauma · NA · recruiting
NCT05812261 — Lesion Characteristics After Pulsed-Field Ablation in Patients With Atrial Fibrillation and a Left Common Ostium · completed
NCT05667610 — Immune-supportive Diet and Gut Permeability in Allergic Children · NA · recruiting
NCT05343403 — Parental Participation on the Neonatal Ward - the neoPARTNER Study · unknown
NCT03646318 — Ketanserin Effects on Peripheral Temperature and Lactate · Phase 4 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06222567 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Onze Lieve Vrouwe Gasthuis
Last refreshed: 24 January 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06222567.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing